Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food

Journal of Clinical Pharmacology

Volumn , Issue , 2016, Pages 1362-1371

  Lamba, Manisha ^a   Wang, Rong ^a   Fletcher, Tracey ^a   Alvey, Christine ^a   Kushner, Joseph ^a   Stock, Thomas C ^a  

^a PFIZER INC   (United States)

Author keywords

extended release; food; multiple dose; once daily; pharmacokinetics; tofacitinib

Indexed keywords

TOFACITINIB;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEFECATION DISORDER; DEFECATION HABIT; DIARRHEA; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; EXTENDED DRUG RELEASE; FEMALE; FOOD; HUMAN; HUMAN EXPERIMENT; IMMEDIATE DRUG RELEASE; LIPID DIET; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MULTIPLE DRUG DOSE; NORMAL HUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STEADY STATE; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84990227017     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.734     Document Type: Article

References (15)

1. Meyer DM, Jesson MI, Li X, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond). 2010;7(1):41.
2. Changelian PS, Moshinsky D, Kuhn CF, et al. The specificity of JAK3 kinase inhibitors. Blood. 2008;111(4):2155–2157.
3. Riese RJ, Krishnaswami S, Kremer J. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol. 2010;24(4):513–526.
4. Cohen S, Zwillich SH, Chow V, LaBadie RR, Wilkinson B. Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment. Br J Clin Pharmacol. 2010;69(2):143–151.
5. Hutmacher MM, Krishnaswami S, Kowalski KG. Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patients. J Pharmacokinet Pharmacodyn. 2008;35(2):139–157.
6. Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012;18(7):527–539.
7. Waterman KC, MacDonald BC, Roy MC. Extrudable core system: development of a single-layer osmotic controlled-release tablet. J Control Release. 2009;134(3):201–206.
8. Lamba M, Wang R, Fletcher T, et al. Pharmacokinetics, bioavailability and safety of a modified release once daily formulation of tofacitinib in healthy volunteers. Ann Rheum Dis. 2014;73(Suppl 2):228. Abstract THU0143.
9. Food and Drug Administration. Guidance for Industry: Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs—General Considerations. 2014. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm389370.pdf.
10. European Medicines Agency. Guideline on quality of oral modified release products. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/07/WC500170465.pdf.
11. Malaterre V, Ogorka J, Loggia N, Gurny R. Oral osmotically driven systems: 30 years of development and clinical use. Eur J Pharm Biopharm. 2009;73(3):311–323.
12. Modi NB, Wang B, Hu WT, Gupta SK. Effect of food on the pharmacokinetics of osmotic controlled-release methylphenidate HCI in healthy subjects. Biopharm Drug Dispos. 2000;21(1):23–31.
13. van den Berg G, van Steveninck F, Gubbens-Stibbe JM, Schoemaker HC, de Boer AG, Cohen AF. Influence of food on the bioavailability of metoprolol from an OROS system; a study in healthy volunteers. Eur J Clin Pharmacol. 1990;39(3):315–316.
14. John VA, Smith SE. Influence of food intake on plasma oxprenolol concentrations following oral administration of conventional and Oros preparations. Br J Clin Pharmacol. 1985;19(Supplement 2):191S–195S.
15. Grundy JS, Foster RT. The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties. Clin Pharmacokinet. 1996;30(1):28–51.